Introducing ImmuNova™:
A Next-Generation Platform for Personalized Immunotherapy Research
ImmuNova™ is our CD34+ NVGF Plus solution that addresses the core drawbacks of traditional CD34+ humanized mouse models—insufficient NK/myeloid lineage expansion, limited HLA matching, and poor engraftment of adult CD34+ cells. By integrating HLA-matched, single-donor mobilized peripheral blood CD34+ cells with in vivo expression of key human cytokines, ImmuNova™ delivers an authentic, fully human immune system for immuno-oncology, vaccine development, and autoimmune disease research.
Key Advantages
-
Reduced Host Immunity vs. NSG/NOG
ImmuNova™ further minimizes murine immune components, creating an expanded niche for human hematopoietic cell engraftment and reducing cross-talk that can compromise experimental outcomes. -
In Vivo long-term Cytokine Expression for a Fully Human Immune System
Balanced levels of cytokines drive robust myeloid, NK, and T-cell development—often underrepresented in conventional models—making ImmuNova™ ideal for precision immunotherapy and translational medicine studies. -
Optimized Cytokine Expression
Maintains immune system stability and lifespan, avoiding the excessive inflammation often seen in specific cytokine-driven models. -
Single-donor, HLA-Typed Scalability
Generates hundreds of humanized mice from a single donor, facilitating large, uniform cohorts for PDX and vaccine evaluations. -
Autologous PDX Potential
Leverages the same patient’s tumor and CD34+ cells, enabling personalized oncology studies that reflect real-world immune functionality. -
Efficient Adult CD34+ Engraftment
Outperforms standard NSG/NOG lines when using MB-CD34+ or other adult sources, promoting higher T-cell differentiation and CD45+ reconstitution. -
Future Directions
Ongoing R&D focuses on lymph node architecture enhancements, ensuring continual evolution to meet advanced translational research needs.
Applications
-
Immuno-Oncology & Cell Therapy: Study checkpoint inhibitors, CAR-T, and novel immunotherapies in a full-spectrum immune context.
-
PDX & Personalized Medicine: Develop patient-specific models for tumor biology, drug screening, and biomarker discovery.
-
Infectious Disease & Vaccine: Test vaccine candidates or pathogen-host interactions with more substantial NK/myeloid functionality.
-
Autoimmune & Inflammatory Disorders: Investigate disease mechanisms and potential interventions in a stable, humanized system.
Request More Information:
For complete datasets, detailed discussion, and NVGF Plus development and performance figures, don't hesitate to contact us to request our comprehensive NVGF Plus White Paper. We look forward to accelerating your translational research with the next generation of humanized mouse models.